Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
ROOT, Switzerland, April 05, 2024--Novocure (NASDAQ: NVCR) today announced 20 presentations on Tumor Treating Fields (TTFields) therapy will be delivered at the American Association for Cancer Research (AACR) Annual Meeting 2024, to be held April 5 to 10 in San Diego.
NovoCure (NVCR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
ROOT, Switzerland, April 01, 2024--Novocure (NASDAQ: NVCR) announced today that it will report financial results for the first quarter 2024 on Thursday, May 2, 2024, before the U.S. financial markets open. Novocure management will host a conference call and webcast to discuss the company’s financial results for the three months ended March 31, 2024, at 8:00 a.m. EDT on Thursday, May 2, 2024. To access the conference call by phone, use the following conference call registration link and dial-in d
Novocure announced encouraging results in a phase 3 trial for its TTFields therapy.
Novocure had good news mixed with some not-so-good news.
NovoCure (NVCR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Novocure stock surged Wednesday after its medtech device nearly doubled the length of time patients with brain tumors lived before worsening.
Novocure said on Wednesday that its cancer therapy met the main goal of a late-stage trial testing it as a treatment for a type of lung cancer. The therapy along with supportive care slowed the spreading of cancer to the brain to 21.9 months compared to 11.3 months for supportive care alone. Novocure said it plans to submit the data to regulatory authorities.
The therapy, which uses a device, slowed the spread of cancer in the brain to 21.9 months, along with supportive care, compared to 11.3 months for supportive care alone in patients with non-small cell lung cancer (NSCLC), the company said in a statement. The device, Tumor Treating Fields, uses a patient-operated device to create electric fields that the company says could disrupt cancer cell growth. The device failed a late-stage trial in ovarian cancer patients last year.
ROOT, Switzerland, March 27, 2024--Novocure (NASDAQ: NVCR) today announced the phase 3 METIS clinical trial met its primary endpoint, demonstrating a statistically significant improvement in time to intracranial progression for adult patients treated with Tumor Treating Fields (TTFields) therapy and supportive care compared to supportive care alone in the treatment of patients with 1-10 brain metastases from non-small cell lung cancer (NSCLC) following stereotactic radiosurgery (SRS). Patients t